Precision Medicine (Rx) Pipeline: Ignyta’s Molecularly Targeted Therapies

At Ignyta, our Rx (therapeutic) efforts are focused on developing and commercializing molecularly targeted therapies that help eradicate cancer. We believe these powerful precision medicines represent the future of cancer treatment, giving healthcare providers new tools in the battle against molecularly defined malignancies.

Learn more below about Ignyta’s portfolio of precision therapeutics in development, and visit our clinical trials page to find out more about getting your patients enrolled in a trial of one of Ignyta’s groundbreaking targeted therapies.


Take a Look into Ignyta’s Development Pipeline

Our precision medicine (Rx) pipeline, working hand-in-hand with our molecular diagnostic (Dx) technologies, creates the combined Rx/Dx capability that sets Ignyta apart from others, resulting in potentially faster determination of patient eligibility for an Ignyta clinical trial.

Ignyta's pipeline of precision cancer medicines in development; targeting the genomic causes of some cancers.
Ignyta's pipeline of precision cancer medicines in development; targeting the genomic causes of some cancers.

By taking several different approaches to halt cancer progression, Ignyta is developing and commercializing molecularly targeted therapies that, sequentially or in combination, eradicate residual disease.

Entrectinib – Targeting NTRK, ROS1, ALK fusions

Currently undergoing STARTRK-2, a global, potentially registration enabling Phase 2 clinical trial, entrectinib is a potent, CNS-active, orally available, selective tyrosine kinase inhibitor of the TRKA, TRKB, TRKC, ROS1, and ALK proteins. This product candidate was designed to target cancers harboring activating molecular alterations to the corresponding subset of oncogenes. Learn more about gene fusions in cancer, data from the entrectinib ongoing Phase I and Phase II trials, and clinical responses. Click here to Learn more about Entrectinib (RXDX-101), and NTRK, ROS1, and ALK Fusions, as well as data from the entrectinib ongoing Phase I and Phase II trials, and clinical responses.

RXDX-105 – Targeting RET and Other Kinase Targets

An orally available, VEGF-sparing, potent RET inhibitor. A Phase Ib basket study of RXDX-105 is currently underway.
Learn more about RET fusions.

Taladegib – Targeting Hh/SMO

A small molecule hedgehog/smoothened inhibitor. In normal cells, the hedgehog molecule acts as a ligand that can bind the smoothened transmembrane receptor and set off a signaling cascade that can influence early development and replication of adult stem cell populations. Stem cells that acquire molecular changes activating the hedgehog/smoothened pathway can transform into tumor precursors; this process has been implicated in some forms of brain cancer, skin cancer, and pancreatic cancer. Targeting these stem cells in combination with other therapeutics could potentially help eradicate residual disease.

RXDX-106 – Targeting TYRO3, AXL, MER

RXDX-106 is a small molecule, pseudo-irreversible inhibitor of the TAM (TYRO3, AXL, and MER) family of receptor tyrosine kinases.  This product candidate is currently in late-stage preclinical development. RXDX-106 binds to each of its targets – for example, as a TYRO3 inhibitor – and forms non-covalent bonds with a slow off-rate that ensure continued signaling attenuation long after the molecule becomes undetectable in the patient’s serum. This could translate into a short half-life followed by a longer period of potential tumor-suppressing activity. It also appears to potentiate the immune system, particularly in combination with other agents.
Learn more about Pan-TAM Inhibitors.

The Rx/Dx Advantage

Decoding the underlying causes of cancer is an evolving field, with much at stake from all sides. Learn more about Ignyta’s Rx/Dx Advantage and how we’re working with healthcare providers to change cancer treatment and care.

Ignyta Scientific Presentations

A database of Ignyta’s clinical, scientific, and technical data on precision therapeutic candidates and diagnostic tests. See Ignyta’s Scientific and Clinical Presentations.